{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:30:32Z","timestamp":1790688632353,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.01123","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T11:48:02Z","timestamp":1597405682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015\u20132018 Years"],"prefix":"10.3389","volume":"11","author":[{"given":"Aneta","family":"Mela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz A.","family":"Poniatowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart\u0142omiej","family":"Drop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Furtak-Niczyporuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Jaroszy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Wrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Staniszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u0105browski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Jagielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Wojciechowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Niewada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1381544","article-title":"Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry","volume":"5","author":"Badora","year":"2017","journal-title":"J. Market Access Health Policy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4543","article-title":"Cancer drugs: high price, uncertain value","volume":"4","author":"Cohen","year":"2017","journal-title":"BMJ"},{"key":"B3","unstructured":"EY Poland Access to innovative cancer drugs in Poland in comparison with selected European Union countries and Switzerland"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40273-017-0559-4","article-title":"The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications","volume":"35","author":"Ferrario","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5639\/gabij.2019.0802.007","article-title":"Pricing of oral generic cancer medicines in 25 European countries; findings and implications","volume":"8","author":"Godman","year":"2019","journal-title":"Generics Biosimilars Initiative J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the market for anticancer drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J. Econom. Perspect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.vhri.2017.07.001","article-title":"Drug Policy in Poland","volume":"13","author":"Jahnz-R\u00f3\u017cyk","year":"2017","journal-title":"Value in Health Regional Issues"},{"key":"B8","article-title":"Refundacja lek\u00f3w w Polsce \u2013 wyk\u0142adnia przepis\u00f3w i efekty ich stosowania","author":"Kaczmarczyk","year":"2015","journal-title":"Warszawa"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2016.02.010","article-title":"Implementation of the 2011 Reimbursement Act in Poland: desired and undesired effects of the changes in reimbursement policy","volume":"120","author":"Kawalec","year":"2016","journal-title":"Health Policy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1017\/S0266462317000563","article-title":"A decade of health technology assessment in Poland","volume":"33","author":"Lipska","year":"2017","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B11","volume-title":"Comparative Health Care Financing Trends in Europe. A retrospective and forward-looking view","year":""},{"key":"B12","volume-title":"What are the major challenges to modern medicine","year":""},{"key":"B13","unstructured":"RSA in Drugs Reimbursement System in Poland and Abroad"},{"key":"B14","unstructured":"r. w sprawie warunk\u00f3w zawierania i realizacji um\u00f3w w rodzaju leczenie szpitalne w zakresie programy lekowe [\u00a722. point 1-3 of regulation no 125\/2017\/DGL of the President of the National Health Fund on requirements for concluding and realising agreements in type: hospital treatment in a range: drug programmes issued on 19 December 2017]2017"},{"key":"B15","unstructured":"r. w sprawie warunk\u00f3w zawierania i realizacji um\u00f3w w rodzaju leczenie szpitalne w zakresie programy lekowe [\u00a73. point 1 of regulation no 125\/2017\/DGL of the President of the National Health Fund on requirements for concluding and realising agreements in type: hospital treatment in a range: drug programmes issued on 19 December 2017]2017"},{"key":"B16","unstructured":"2017"},{"key":"B17","unstructured":""},{"key":"B18","unstructured":"r. o refundacji lek\u00f3w, \u015brodk\u00f3w spo\u017cywczych specjalnego przeznaczenia \u017cywieniowego oraz wyrob\u00f3w medycznych [Act of May 12, 2011 on the reimbursement of pharmaceuticals, foodstuffs with special nutritional use, and medical devices]2011"},{"key":"B19","unstructured":"r. o \u015bwiadczeniach opieki zdrowotnej finansowanych ze \u015brodk\u00f3w publicznych [Act of 27 August 2004 on publicly-funded healthcare services]2004"},{"key":"B20","unstructured":"r. Prawo farmaceutyczne (tj. Dz. U. z 2017 r. poz. 2211 z p\u00f3\u017an. zm.) [Act of September 6, 2001 on the pharmaceutical law]2001"},{"key":"B21","unstructured":"r. Prawo farmaceutyczne (tj. Dz. U. z 2017 r. poz. 2211 z p\u00f3\u017an. zm.) [Act of September 6, 2001 on the pharmaceutical law]2001"},{"key":"B22","unstructured":"r. w sprawie warunk\u00f3w zawierania i realizacji um\u00f3w w rodzaju leczenie szpitalne w zakresie programy lekowe [Appendix no. 17 to the regulation no 125\/2017\/DGL of the President of the National Health Fund on requirements for concluding and realising agreements in type: hospital treatment in a range: drug programmes issued on 19 December 2017]2017"},{"key":"B23","unstructured":"r. w sprawie warunk\u00f3w zawierania i realizacji um\u00f3w w rodzaju leczenie szpitalne w zakresie programy lekowe [Appendix no. 1 to the regulation no 125\/2017\/DGL of the President of the National Health Fund on requirements for concluding and realising agreements in type: hospital treatment in a range: drug programmes issued on 19 December 2017]2017"},{"key":"B24","unstructured":"r. w sprawie warunk\u00f3w zawierania i realizacji um\u00f3w w rodzaju leczenie szpitalne w zakresie programy lekowe [Appendix no. 2 to the regulation no 125\/2017\/DGL of the President of the National Health Fund on requirements for concluding and realising agreements in type: hospital treatment in a range: drug programmes issued on 19 December 2017]2017"},{"key":"B25","unstructured":"r. w sprawie warunk\u00f3w zawierania i realizacji um\u00f3w w rodzaju leczenie szpitalne w zakresie programy lekowe [Appendix no. 3 to the regulation no 125\/2017\/DGL of the President of the National Health Fund on requirements for concluding and realising agreements in type: hospital treatment in a range: drug programmes issued on 19 December 2017]2017"},{"key":"B26","unstructured":"r. w sprawie warunk\u00f3w zawierania i realizacji um\u00f3w w rodzaju leczenie szpitalne w zakresie programy lekowe [Appendix no. 4 to the regulation no 125\/2017\/DGL of the President of the National Health Fund on requirements for concluding and realising agreements in type: hospital treatment in a range: drug programmes issued on 19 December 2017]2017"},{"key":"B27","unstructured":"r. w sprawie warunk\u00f3w zawierania i realizacji um\u00f3w w rodzaju leczenie szpitalne w zakresie programy lekowe [Appendix no. 5 to the regulation no 125\/2017\/DGL of the President of the National Health Fund on requirements for concluding and realising agreements in type: hospital treatment in a range: drug programmes issued on 19 December 2017]2017"},{"key":"B28","unstructured":"r. w sprawie warunk\u00f3w zawierania i realizacji um\u00f3w w rodzaju leczenie szpitalne w zakresie programy lekowe [Appendices no. 6-16 to the regulation no 125\/2017\/DGL of the President of the National Health Fund on requirements for concluding and realising agreements in type: hospital treatment in a range: drug programmes issued on 19 December 2017]2017"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T11:48:13Z","timestamp":1597405693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":28,"alternative-id":["10.3389\/fphar.2020.01123"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.01123","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"article-number":"1123"}}